ClinicalTrials.gg
CompletedNCT04198363Updated Sep 7, 2023Results posted

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

A Phase 3 interventional study of Vonoprazan and Amoxicillin in Helicobacter Pylori, sponsored by Takeda. Completed at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of helicobacter pylori (HP) eradication with bismuth-containing quadruple therapy with vonoprazan versus esomeprazole in all HP-positive participants.

Read the detailed description

The drug being tested in this study is called vonoprazan (TAK-438). Vonoprazan is being tested to treat people who have helicobacter pylori infection.

The study is planned to enroll 425 patients at the beginning and will enroll a maximum of approximately 510 patients based on the interim analysis results. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

Vonoprazan 20 mg

Esomeprazole 20 mg

All participants will be asked to take one tablet in combination with bismuth containing quadruple therapy (amoxicillin, clarithromycin and bismuth potassium citrate) twice at the same time each day throughout the study.

This multi-center trial will be conducted in China. The overall time to participate in this study is 10 weeks. Participants will make multiple visits to the clinic, and 28 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Helicobacter Pylori

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Helicobacter pylori (HP)-positive participants as determined by \^13C-urea breath test (\^13C-UBT) at the start of the study (Visit 1 [screening]) and who require HP eradication in Physician judgment.

Exclusion criteria

Exclusion Criteria:

  1. Participant had any of the following conditions at the start of the study (Visit 1, screening): acute upper gastrointestinal bleeding, active gastric ulcer (GU) or duodenal ulcer (DU) characterized by defective mucos with white coating (with or without adherent blood clots) 3 mm or more in size, acute gastric mucosal lesion (AGML), or acute duodenal mucosal lesion (ADML). However, participants with gastritis, gastric or duodenal erosion are permitted to participate.
  2. Participants with Zollinger-Ellison syndrome or gastric acid hypersecretion or those with a history of gastric acid hypersecretion.
  3. Participant has a history of or was treated for malignancy within 5 years before the start of the screening visit (the participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ).
  4. Participant has a known acquired immunodeficiency syndrome or hepatitis infection, including hepatitis virus carriers ( surface antigen [HBsAg] or virus [HCV]- antibody-positive).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (actual)

Study arms

  • Experimental
    Vonoprazan 20 mg

    Vonoprazan 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.

    Drug: Vonoprazan · Drug: Amoxicillin · Drug: Clarithromycin · Drug: Bismuth Potassium citrate

  • Active comparator
    Esomeprazole 20 mg

    Esomeprazole 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.

    Drug: Amoxicillin · Drug: Clarithromycin · Drug: Bismuth Potassium citrate · Drug: Esomeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment

    HP infection status was determined by \^13C Urea Breath Test (\^13C-UBT). The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory. The percentages are rounded off to report the nearest ten.

    Time frame: Week 4 post-treatment

07

Results

Posted Sep 7, 2023

Participant flow

Participants took part in the study at 29 investigative sites in China from 30 April 2020 to 25 November 2021.

Participant flow — Overall Study
MilestoneVonoprazan 20 mgEsomeprazole 20 mg
Started256254
Completed254252
Not completed22
Withdrew: Adverse event11
Withdrew: Voluntary withdrawal by subject01
Withdrew: Reason not specified10

Outcome measures

PrimaryPercentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment

HP infection status was determined by \^13C Urea Breath Test (\^13C-UBT). The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory. The percentages are rounded off to report the nearest ten.

Time frame:
Week 4 post-treatment
Reported as:
Number · percentage of participants
Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment
percentage of participantsVonoprazan 20 mgEsomeprazole 20 mg
Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment86.886.7
Statistical analysis
  • Vonoprazan 20 mg vs Esomeprazole 20 mg · Farrington and Manning Test · p = =0.0009 · Difference in proportions: 0.1 · 95% CI -5.95 to 6.17Difference in proportions for vonoprazan versus esomeprazole was analyzed and the 2-sided Wald confidence interval was used for determining the 95% confidence interval.

Adverse events

Collected over From first dose of study drug up to approximately 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan 20 mg0/256 (0%)3/256 (1.2%)110/256 (43%)
Esomeprazole 20 mg0/254 (0%)5/254 (2%)91/254 (35.8%)
Most frequent serious events
Most frequent serious events
EventVonoprazan 20 mgEsomeprazole 20 mg
Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1510/164
Cervical dysplasiaReproductive system and breast disorders0/1511/164
Ovarian cyst rupturedReproductive system and breast disorders0/1511/164
Chronic gastritisGastrointestinal disorders0/2561/254
Enteritis infectiousInfections and infestations0/2561/254
Meniscus injuryInjury, poisoning and procedural complications0/2561/254
Drug eruptionSkin and subcutaneous tissue disorders0/2561/254
Arrhythmia supraventricularCardiac disorders1/2560/254
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2560/254
Most frequent other events
Most frequent other events
EventVonoprazan 20 mgEsomeprazole 20 mg
DysgeusiaNervous system disorders83/25674/254
Protein urine presentInvestigations18/25615/254
Hepatic function abnormalHepatobiliary disorders17/2569/254
Faeces discolouredGastrointestinal disorders13/2568/254

Baseline characteristics

Full analysis set (FAS) included all randomized participants who received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Vonoprazan 20 mgEsomeprazole 20 mgTotal
Mean39.5 ± 12.2938.3 ± 12.1338.9 ± 12.21
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan 20 mgEsomeprazole 20 mgTotal
Female151164315
Male10590195
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vonoprazan 20 mgEsomeprazole 20 mgTotal
Hispanic or Latino000
Not Hispanic or Latino256254510
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vonoprazan 20 mgEsomeprazole 20 mgTotal
American Indian or Alaska Native000
Asian256254510
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Vonoprazan 20 mgEsomeprazole 20 mgTotal
China256254510
Height
Height(cm)Vonoprazan 20 mgEsomeprazole 20 mgTotal
Mean164.9 ± 8.23164.3 ± 7.70164.6 ± 7.97
Weight
Weight(kg)Vonoprazan 20 mgEsomeprazole 20 mgTotal
Mean61.90 ± 10.57961.15 ± 9.56861.53 ± 10.087
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vonoprazan 20 mgEsomeprazole 20 mgTotal
Mean22.66 ± 2.91322.61 ± 2.73522.63 ± 2.823
08

Study locations

29 sites
  • Friendship Hospital, Capital Medical University
    Beijing, Beijing 100000, China
  • Peking University Third Hospital
    Beijing, Beijing 100000, China
  • Fuzhou General Hospital of Nanjing Military Command
    Fuzhou, Fujian 350000, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361004, China
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian 361004, China
  • The First People's Hospital of Foshan
    Foshan, Guangdong 528000, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510180, China
  • Haikou people's Hosptial
    Haikou, Hainan 570208, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Xiangya Hospital of Central South University, Digestive Department
    Changsha, Hunan 410008, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 213003, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210029, China
  • Yangzhou First People's Hospital
    Yangzhou, Jiangsu 225000, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225001, China
  • The Third Hospital of Nanchang
    Nanchang, Jiangxi 330000, China
  • The First Affiliated Hospital of Nanchang University Digestive Department
    Nanchang, Jiangxi 330006, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Shanghai East Hospital
    Shanghai, Shanghai 200000, China
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai 200000, China
  • Ruijin Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200025, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710004, China
  • First Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830054, China
  • The Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in Nov 2021, 18 months.

Results were first posted in Sep 2023, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2019
First posted
Dec 13, 2019
StartActual
Apr 30, 2020
Primary completionActual
Nov 1, 2021
CompletionActual
Nov 25, 2021
Results first posted
Sep 7, 2023
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04198363
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Apr 30, 2020
Primary completion
Nov 1, 2021
Completion
Nov 25, 2021
Results posted
Sep 7, 2023
Last update
Sep 7, 2023

Study contacts

Study Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion